Financial Performance - Total current assets decreased from $257,767,000 as of December 31, 2024, to $206,864,000 as of September 30, 2025, representing a decline of approximately 19.7%[20] - Revenue from collaboration agreements for the three months ended September 30, 2025, was $11,230,000, down 26.1% from $15,362,000 for the same period in 2024[23] - Total operating expenses increased to $45,642,000 for the three months ended September 30, 2025, compared to $43,606,000 for the same period in 2024, marking an increase of 4.7%[23] - The net loss for the three months ended September 30, 2025, was $32,166,000, compared to a net loss of $24,666,000 for the same period in 2024, reflecting an increase in loss of 30.4%[23] - For the nine months ended September 30, 2025, the net loss was $84.5 million, compared to a net loss of $70.7 million for the same period in 2024, reflecting an increase in losses of approximately 19.7%[38] - The company reported a net loss of $84.5 million for the nine months ended September 30, 2025, compared to a net loss of $70.7 million for the same period in 2024, resulting in an accumulated deficit of $718.2 million as of September 30, 2025[167] Assets and Liabilities - Cash and cash equivalents increased from $55,499,000 as of December 31, 2024, to $58,809,000 as of September 30, 2025, an increase of approximately 4.1%[20] - The accumulated deficit grew from $633,699,000 as of December 31, 2024, to $718,207,000 as of September 30, 2025, indicating an increase of 13.3%[20] - The total liabilities decreased from $133,616,000 as of December 31, 2024, to $111,080,000 as of September 30, 2025, a reduction of approximately 16.8%[20] - The total stockholders' equity decreased from $215,986,000 as of December 31, 2024, to $154,408,000 as of September 30, 2025, a decline of approximately 28.5%[20] - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling approximately $199.8 million[140] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $79,258,000, slightly up from $78,124,000 for the same period in 2024, an increase of 1.5%[23] - The company continues to focus on research and development activities, leveraging its proprietary TORPEDO platform to advance targeted oncology programs[36] - The company expects research and development expenses to continue to increase substantially in connection with planned preclinical and clinical development activities[124] - The company anticipates significant operating losses to continue as it advances preclinical programs and product candidates through clinical development[139] - Cemsidomide, the company's lead product candidate, is in clinical development for multiple myeloma and has shown compelling anti-myeloma activity in recent trials[114] Collaborations and Agreements - Under the Pfizer Agreement, Pfizer will supply elranatamab for a Phase 1b trial at no cost, while the company will sponsor and pay for the trial costs[58] - The MKDG Agreement includes an upfront cash payment of $16 million and potential milestone payments totaling approximately $740 million, plus tiered royalties on net sales[60] - The company earned a $1 million milestone payment in April 2025 for achieving a discovery milestone related to the MKDG collaboration[60] - The Betta Pharma License Agreement includes an upfront cash payment of $10.0 million and potential milestone payments of up to $357.0 million, plus tiered royalties on net sales in Greater China[66] - The company received a $45.0 million nonrefundable upfront payment from Biogen as part of the collaboration agreement[86] Market and Competition - The company faces substantial competition in the targeted protein degradation (TPD) space from numerous biotechnology and pharmaceutical firms, including Arvinas, Inc. and BioTheryX, Inc.[212] - Competitors possess significantly greater financial resources and expertise in R&D, manufacturing, and regulatory approvals, which may hinder the company's market position[214] - The competition includes not only other TPD therapies but also small molecule, antibody, T cell, and gene therapies, which could impact the company's market entry[213] Financial Strategy and Future Outlook - The company may need to obtain substantial additional financing to support its operations and long-term business plan, as it cannot estimate future capital requirements due to various risks and uncertainties[147] - The company has entered into collaborations with partners such as Roche and Biogen, but does not have any committed external sources of funds as of September 30, 2025[147] - The company anticipates incurring significant expenses and increasing operating losses for at least the next several years due to ongoing research and development activities[168] - The company will need to raise substantial additional capital to fund product development and commercialization efforts[176] Clinical Trials and Regulatory Challenges - The company has not yet demonstrated the ability to successfully complete clinical trials or obtain marketing approvals for its product candidates[178] - The regulatory approval process for the company's novel product candidates may be more expensive and time-consuming compared to other therapeutics[188] - The company may face unforeseen expenses and challenges as it transitions from a research-focused entity to one capable of supporting commercial activities[179] - Clinical trials are lengthy and expensive, with significant uncertainty regarding outcomes, and the company may incur unexpected costs or delays[205]

Financial Performance - License revenue for the nine months ended September 30, 2025, was $70,000,000, compared to $0 for the same period in 2024[19]. - Net income for the nine months ended September 30, 2025, was $37,483,000, a significant improvement from a net loss of $53,691,000 in the same period of 2024[21]. - The company reported a net loss of $8,498,000 for the three months ended September 30, 2025, compared to a loss of $15,557,000 for the same period in 2024[21]. - The company reported a comprehensive income of $37,601,000 for the nine months ended September 30, 2025, compared to a comprehensive loss of $53,557,000 in 2024[21]. - For the nine months ended September 30, 2025, the company recorded a net loss of $37,483 million, compared to a net loss of $53,691 million for the same period in 2024[66]. Assets and Liabilities - Total assets increased to $157,733,000 as of September 30, 2025, up from $122,640,000 as of December 31, 2024, representing a growth of 28.6%[18]. - Total liabilities decreased to $31,581,000 as of September 30, 2025, from $39,355,000 as of December 31, 2024, a reduction of 19.7%[18]. - Stockholders' equity increased to $126,152,000 as of September 30, 2025, up from $83,285,000 as of December 31, 2024, reflecting a growth of 51.5%[18]. - Total current assets increased to $138,992,000 as of September 30, 2025, from $101,176,000 as of December 31, 2024, representing a 37.2% increase[18]. - The total accrued expenses and other current liabilities as of September 30, 2025, were $14,570 million, a decrease from $16,566 million as of December 31, 2024[57]. Cash Flow - Cash flows from operating activities generated $36,401,000 for the nine months ended September 30, 2025, compared to cash used of $47,248,000 in 2024[24]. - Cash and cash equivalents decreased to $30,864,000 from $36,437,000, a decline of 15.5%[18]. - The company expects its cash, cash equivalents, and investments to fund operations for at least the next 12 months[33]. Research and Development - The company incurred research and development expenses of $14,482,000 for Silevertinib for the nine months ended September 30, 2025, compared to $17,349,000 in 2024[78]. - Research and development expenses for the nine months ended September 30, 2025, were $27,262,000, down 30.0% from $39,015,000 in the same period of 2024[19]. Licensing Agreements - The company received an upfront payment of $70 million from Servier Pharmaceuticals LLC under a global licensing agreement for BDTX-4933[31]. - The company is eligible to receive up to $710 million in development and commercial sales milestone payments from the Servier Agreement[31]. - The Company assessed the Servier Agreement under ASC 606, determining that the transaction price included fixed consideration of $70,000,000 recognized upon contract execution[81]. - During the nine months ended September 30, 2025, the Company recorded $70,000,000 in license revenue from the Servier Agreement, with no revenue recorded in the same period of 2024[84]. Stock and Compensation - The company reported a weighted average common shares outstanding of 56,799,755 for the nine months ended September 30, 2025, compared to 54,498,037 for the same period in 2024[19]. - The Company recorded stock-based compensation expense of $5,216 million for the nine months ended September 30, 2025, compared to $8,991 million for the same period in 2024[60]. - The total unrecognized compensation cost related to unvested stock options was $9.256 million, expected to be recognized over a weighted average period of 2.3 years[62]. Future Outlook - The company plans to seek additional funding through various means, including equity financings and collaborations[34]. - The company continues to monitor macroeconomic developments that may impact its business[39]. - The company has had recurring losses and negative cash flows from operations since inception[32].

Exhibit 99.1 Insulet Reports Third Quarter 2025 Results Raises Full Year Revenue and Margin Guidance Third Quarter Financial Highlights: Recent Strategic Highlights: "We delivered strong third quarter results, a testament to our team's exceptional performance and the transformative power of Omnipod 5 for people living with diabetes," said Ashley McEvoy, President and CEO. "Our continued meaningful engagement with physicians, partners, investors, and our incredible Podder community further reinforces our uni ...

Investigational Therapies - The company is developing three investigational therapies: avexitide for PBH, AMX0035 for Wolfram syndrome, and AMX0114 for ALS[80]. - Avexitide has received Breakthrough Therapy Designation from the FDA for both PBH and congenital hyperinsulinism, with no FDA-approved therapies currently available for PBH[81]. - The pivotal Phase 3 LUCIDITY trial for avexitide began in April 2025, with approximately 75 participants expected to complete recruitment by Q1 2026 and topline data anticipated in Q3 2026[83]. - In the Phase 2 PREVENT trial, avexitide demonstrated a 21% and 26% increase in mean plasma glucose nadir after treatment with 30 mg twice daily and 60 mg once daily, respectively, compared to placebo[84]. - AMX0035 is being investigated for its potential to slow neurodegeneration in Wolfram syndrome, a rare disorder affecting approximately 3,000 people in the U.S.[89]. - The Phase 2 HELIOS trial of AMX0035 showed sustained improvements in pancreatic function and glycemic control through Week 48, with all adverse events being mild or moderate[93]. - AMX0114 has received Fast Track designation from the FDA for ALS, with the first participant dosed in the Phase 1 LUMINA trial in April 2025[95][97]. - The company plans to initiate a pivotal Phase 3 trial for AMX0035 in Wolfram syndrome in the second half of 2026, pending FDA alignment[94]. - The company announced the discontinuation of the ORION program for AMX0035 in progressive supranuclear palsy due to lack of efficacy[98]. Financial Performance - For the three months ended September 30, 2025, product revenue was $0, a decrease of 100% compared to $416,000 in the same period of 2024[108]. - Research and development expenses for the three months ended September 30, 2025 were $19.9 million, down 7% from $21.2 million in 2024[111]. - The decrease in research and development expenses was primarily due to a $1.9 million reduction related to AMX0035 for PSP and a $4.1 million decrease for ALS, offset by a $4.8 million increase for avexitide[112]. - Selling, general and administrative expenses decreased to $16.2 million for the three months ended September 30, 2025, a 9% decline from $17.8 million in 2024[113]. - Total operating expenses for the three months ended September 30, 2025 were $36.0 million, a 53% decrease from $76.1 million in 2024[108]. - For the nine months ended September 30, 2025, product revenue was $0, a decrease of 100% from $88.0 million in the same period of 2024[114]. - Research and development expenses for the nine months ended September 30, 2025 were $69.2 million, down 15% from $81.2 million in 2024[114]. - The company recorded approximately $118.7 million in charges related to inventory write-downs and losses on firm purchase commitments for the nine months ended September 30, 2024[116]. - Selling, general and administrative expenses fell to $47.5 million for the nine months ended September 30, 2025, compared to $97.2 million in 2024, a decrease of 51%[119]. Cash and Financing - The company raised approximately $65.5 million from the January 2025 Offering and $190.7 million from the September 2025 Offering, totaling $257.2 million in financing activities for the nine months ended September 30, 2025[121][122]. - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $344.0 million, with an accumulated deficit of $718.4 million[123]. - The net cash used in operating activities was $95.4 million for the nine months ended September 30, 2025, compared to $108.6 million in 2024, a decrease of 12%[130]. - The company expects to finance near-term operations through existing cash and potential equity or debt financing, with no assurances that additional funding will be available on acceptable terms[126]. - The company anticipates an increase in expenses related to ongoing research and development activities, particularly for avexitide and AMX0035, as well as potential acquisitions or in-licensing of new product candidates[127]. - The net cash used in investing activities was $15.4 million for the nine months ended September 30, 2025, primarily due to $201.4 million in purchases of marketable securities[135]. Restructuring and Workforce - The restructuring plan announced in April 2024 resulted in a workforce reduction of approximately 70% and a decrease in external financial commitments[105]. - The company did not recognize any restructuring expenses for the nine months ended September 30, 2025, following approximately $22.9 million in restructuring costs in the same period of 2024[120]. Research and Development Focus - Research and development expenses primarily consist of costs related to avexitide, AMX0035, AMX0114, and other potential future product candidates[99]. - The significant decrease in R&D expenses was primarily due to a $26.6 million reduction in spending on AMX0035 for ALS treatment following the PHOENIX trial results[118].

Exhibit 99.1 Commerce Announces Third Quarter 2025 Financial Results Third Quarter Total Revenue of $86.0 Million, an Increase of 3% Versus Prior Year. Total ARR of $355.7 Million, an Increase of 2% Versus Prior Year. Enterprise ARR of $269.2 Million, an Increase of 5% Versus Prior Year AUSTIN, Texas – November 6, 2025 – Commerce.com, Inc. (Nasdaq: CMRC) (formerly BigCommerce Holdings, Inc.), a provider of an open, intelligent ecosystem of technology solutions that empower businesses to unlock data potentia ...

Financial Performance - Total revenues and other income for Q3 2025 reached $15,522 million, a 14% increase compared to Q3 2024[2] - Net income for Q3 2025 was $1,726 million, down 16% from $2,059 million in Q3 2024[4] - Basic earnings per share for Q3 2025 was $1.38, a decrease of 22% from $1.77 in Q3 2024[2] - The company reported a total of $12,594 million in costs and expenses for Q3 2025, reflecting a 21% increase from Q3 2024[2] - Adjusted earnings for Q3 2025 were $2,007 million, compared to $2,081 million in Q3 2024, indicating a decline of 4%[4] - The company’s total equity in earnings of affiliates for Q3 2025 was $345 million, a decrease of 22% from $441 million in Q3 2024[2] Taxation - The effective income tax rate for Q3 2025 was 41.0%, up from 36.4% in Q3 2024[3] - Adjusted effective income tax rate for the consolidated entity was 37.6% year-to-date in 2025, up from 35.5% in 2024[5] - The income tax provision for the total company was $67 million year-to-date in 2025[6] Assets and Liabilities - Total assets increased to $124.254 billion in Q1 2025, compared to $122.780 billion in Q4 2024[7] - Cash and cash equivalents stood at $6.309 billion in Q1 2025, a rise from $5.607 billion in Q4 2024[7] - Total current liabilities rose to $13.329 billion in Q1 2025, up from $12.124 billion in Q4 2024[7] - Total equity reached $65.238 billion in Q1 2025, compared to $64.796 billion in Q4 2024[7] Special Items and Expenses - The company reported a total of $226 million in special items for the year-to-date in 2025, with significant gains from asset sales[6] - The company incurred transaction, integration, and restructuring expenses totaling $499 million in 2024[6] Production and Exploration - Total production for 2024 is projected at 2,393 MBOED, with a significant increase from 1,987 MBOED in 2023[9] - Crude oil production from consolidated operations increased to 1,153 MBD in Q1 2025, up from 1,058 MBD in Q4 2024[9] - Natural gas production reached 4,081 MMCFD year-to-date in 2025, compared to 3,433 MMCFD in 2024[9] - Total exploration expenses for 2024 amounted to $355 million, with a breakdown of $158 million for U.S. exploration and $197 million for international exploration[10] Cash Flow and Capital Expenditures - Net cash provided by operating activities for the full year 2024 is $20,124 million, with Q4 contributing $4,457 million[8] - Cash flows from investing activities show a net cash used of $11,150 million for the full year 2024, with Q4 at $2,200 million[8] - The company reported a net cash used in financing activities of $8,835 million for the full year 2024, with Q4 at $1,769 million[8] - Capital expenditures in Alaska for Q4 2024 are $1,092 million, contributing to a total of $3,194 million for the full year[8] Debt and Equity - Total debt at the end of 2024 was $24.324 billion, with a debt-to-capital ratio of 27%[13] - Equity at the end of 2024 was $64.796 billion, showing a slight increase from $49.325 billion at the beginning of the year[13] Average Realized Prices - Average realized prices for crude oil decreased to $67.34 per BOE in 2025, down from $76.74 per BOE in 2024[9] - The average price of WTI crude oil was $66.70 per barrel year-to-date in 2025, reflecting a decline from $75.72 per barrel in 2024[9] - The average realized price for natural gas was $4.69 per MCF year-to-date in 2025, compared to $2.27 per MCF in 2024[9] - The average realized price for crude oil in Alaska was $81.73 per barrel for the full year 2024, while the total consolidated operations averaged $76.74 per barrel[12]

Financial Performance - As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $48.1 million, an increase from $34.4 million at the end of 2024[11][24] - Total operating expenses for the three months ended September 30, 2025, were $14.7 million, compared to $12.5 million for the same period in 2024, representing a 17.7% increase[11][22] - The net loss for the three months ended September 30, 2025, was $14.4 million, compared to a net loss of $12.5 million for the same period in 2024, indicating a 15.4% increase in losses[11][22] - The total net loss for the nine months ended September 30, 2025, was $40.0 million, compared to a net loss of $27.5 million for the same period in 2024, reflecting a 45.4% increase in losses[11][22] Drug Development and Regulatory Updates - The FDA has accepted the New Drug Application (NDA) for cytisinicline for smoking cessation, with a Prescription Drug User Fee Act (PDUFA) targeted action date set for June 20, 2026[3][5] - Cytisinicline demonstrated significantly higher smoking abstinence rates compared to placebo in Phase 3 trials involving over 2,000 participants[5][11] - Achieve Life Sciences was awarded the FDA Commissioner's National Priority Voucher for cytisinicline for vaping cessation, one of only nine therapies to receive this designation[6][3] - New post hoc data published in Thorax showed that cytisinicline improved smoking quit rates in adults with chronic obstructive pulmonary disease (COPD), based on over 1,600 participants[7][8] - The ORCA-OL long-term safety trial concluded with all 334 participants completing one year of treatment, exceeding FDA's requested thresholds for patient exposure prior to approval[9][11] Leadership Changes - The company appointed Erik Atkisson as Chief Legal Officer, bringing over 25 years of legal experience in the pharmaceutical and biotechnology industries[10][8]

Exhibit 99.1 Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights NEW HAVEN, Conn., Nov. 06, 2025 – Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended September 30, 2025, and provided recent business highlights. "With a strengthened balance sheet and a clear path forward for VYD2311 with recent IND clearance and U.S. Food and Drug Administration (FDA) alignment, Invivyd is well-poised to provide Americans with antibody protection as an alterna ...

Exhibit 99.1 N-able Announces Third Quarter 2025 Results Delivers ARR Growth of 14% Year-Over-Year Exceeds Third Quarter Revenue and Adjusted EBITDA Guidance BURLINGTON, Massachusetts - November 6, 2025 - N-able, Inc. (NYSE:NABL), a global software company delivering an end- to-end cyber resilience platform, today reported results for its third quarter ended September 30, 2025. "Our strong results reflect robust demand for cybersecurity and the rising strategic relevance of N-able," said N-able president an ...

Financial Performance - Total revenues for Q3 2025 were $663.7 million, a 1.6% decrease from $674.2 million in Q3 2024[18] - Net loss for Q3 2025 was $11.4 million, or $0.04 loss per diluted share, compared to a net loss of $3.7 million, or $0.01 loss per diluted share in Q3 2024[26] - Adjusted FFO for Q3 2025 was $100.7 million, or $0.35 per diluted share, consistent with Q3 2024[28] - Core EBITDA for Q3 2025 was $148.3 million, a decrease of $9.0 million, or 5.7% from $157.2 million in Q3 2024[27] - Core FFO for Q3 2025 was $81.7 million compared to $83.9 million for Q3 2024[28] - NAREIT FFO for Q3 2025 was $43,151,000, down 22% from $55,540,000 in Q3 2024[81] - Core FFO for Q3 2025 was $81,747,000, a decrease of 2.6% from $83,897,000 in Q3 2024[81] - Adjusted FFO for Q3 2025 was $100,681,000, slightly up from $100,137,000 in Q3 2024, indicating a 0.5% increase[81] - Total revenues for Q3 2025 were $663,665,000, down 1.5% from $674,171,000 in Q3 2024[84] - Operating income for the three months ended September 30, 2025, was $16.8 million, down from $27.2 million in the prior year[76] Revenue Breakdown - Global Warehouse same store revenues decreased 1.6% on an actual basis compared to Q3 2024[18] - Global Warehouse total revenues for the three months ended September 30, 2025, were $607,014, a decrease of 0.8% compared to $612,181 in 2024[32] - Same store total revenues were $586,524, down 1.6% from $595,829 in 2024[37] - Non-same store revenues for the three months ended September 30, 2025, totaled $20,490,000, an increase from $16,352,000 in 2024[41] - Non-same store revenues totaled $56,804, with a contribution (NOI) of $5,363 for the nine months ended September 30, 2025[54] - Total revenues for the three months ended September 30, 2025, were $663,665,000, a decrease of 1.5% compared to $674,171,000 for the same period in 2024[1] Operational Metrics - Average economic occupied pallets decreased by 4.2% to 4,057 from 4,237 in 2024[32] - Economic occupancy percentage fell by 290 basis points to 73.8% compared to 76.7% in 2024[32] - Same store average economic occupied pallets declined by 4.1% to 3,969 from 4,137 in 2024[37] - Same store economic occupancy percentage dropped by 280 basis points to 75.5% compared to 78.3% in 2024[37] - The average economic occupancy percentage for the warehouse segment decreased to 74.1% from 78.1% in the prior year, representing a decline of 400 basis points[46] - The average physical occupied pallets decreased to 3,467 for the nine months ended September 30, 2025, down 7.4% from 3,744 in 2024[46] Cost and Expenses - Total selling, general and administrative expenses guidance for 2025 is $270 million to $280 million, including $23 million to $25 million for share-based compensation[20] - The total same store cost of operations for Q3 2025 was $391.3 million, up from $373.9 million in Q2 2025, reflecting a 4.0% increase[124] - Selling, general, and administrative expenses increased to $(70,982,000) for the three months ended September 30, 2025, compared to $(63,663,000) in 2024, an increase of 11.5%[1] - Repair and maintenance expenses totaled $30.8 million for the three months ended September 30, 2025, compared to $33.0 million for the same period in 2024[111] Debt and Liquidity - As of September 30, 2025, the company had total liquidity of approximately $798.9 million, including cash and available capacity on its revolving credit facility[64] - Total net debt outstanding was approximately $4.1 billion, with a net debt to pro forma Core EBITDA ratio of approximately 6.7x[64] - Total debt outstanding as of September 30, 2025, was $4,127,571,000, with a weighted average effective interest rate of 4.15%[86] - The Company’s total debt as a percentage of total assets was 33%, well below the 60% limit set by debt covenants[97] - The Company’s interest coverage ratio was 3.6x, exceeding the required minimum of 1.5x as of September 30, 2025[97] Strategic Initiatives - The company aims to enhance efficiency and reduce costs through its transportation services, including consolidation and freight management[2] - The third-party managed segment is expected to drive growth by providing integrated services to food manufacturers and retailers, enhancing operational efficiency[3] - The company has four sites in the development and expansion phase that will be added to the non-same store pool when operations commence[42] - The Company completed the Houston acquisition on March 17, 2025, for total cash consideration of $108.4 million, enhancing its market position[113] - The company has 5 projects in process, with a total estimated cost of $243 million and an expected stabilized NOI of $50 million[121] Dividend and Shareholder Returns - The Company's Board of Directors declared a 5% increase in the dividend to $0.23 per share for Q3 2025, paid on October 15, 2025[66] Miscellaneous - The Company utilizes various non-GAAP financial measures, including NAREIT FFO and Core EBITDA, to supplement its performance analysis[68] - All quarterly amounts and non-GAAP disclosures within this filing shall be deemed unaudited[148] - The document indicates a total of 33 references to key financial data[149]